Management of Early-Stage HER2-Positive Breast Cancer

Podcast

In the second segment, Dr Pegram and colleagues discuss the clinical implications of the data from select trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Related Videos
Rita Nanda, MD
Siddartha Yadav, MD, FACP
Nan Chen, MD
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Ko Un “Clara” Park, MD
Erin Frances Cobain, MD
Video 3 - "5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer"
Carlos Arteaga, MD
Video 2 - "NCCN Guidelines vs Real-World Practice: Risk Stratifying HR+/HER2- Early Breast Cancer"
Related Content
Subcutaneous Atezolizumab in Cancer: © vxnaghiyev - stock.adobe.com

Health Canada Green Lights Subcutaneous Atezolizumab for Lung, Breast, and Liver Cancer

April 23rd 2024
Article
Andrew J. Wagner, MD, PhD, medical director, Ambulatory Oncology, senior physician, Dana-Faber Cancer Institute; associate professor, medicine, Harvard Medical School

Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa

March 28th 2024
Podcast
Anne Favret, MD

Examining the Evolution of Treatment With CDK4/6 Inhibitors in Metastatic Breast Cancer

April 12th 2024
Article
Stephen Bagley, MD, MSCE, assistant professor, medicine, hematology-oncology, the Hospital of the University of Pennsylvania; section chief, Neuro-Oncology, assistant professor, medicine, neurosurgery, Penn Medicine

Bagley Summarizes the ACTION trial of ONC201 in H3 K27M–Mutant Diffuse Midline Gliomas

March 21st 2024
Podcast
Karen Pinilla Alba, MD

Olaparib With Chemotherapy Does Not Elicit Improved Outcomes vs Chemotherapy Alone in BRCA Wild-Type TNBC

April 8th 2024
Article
Timothy A. Yap, MD

Saruparib Generates Early Efficacy and Safety Signals in HRR-Mutant Advanced Breast Cancer

April 8th 2024
Article